CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2004-08-03): Hepatitis C virus-like particles induce immune responses in baboons

Science

Hepatitis C virus-like particles induce immune responses in baboons

Last Updated: 2004-08-03 11:25:24 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Hepatitis C virus-like particles (HCV-LP) induce both humoral and cellular immune responses in baboons, according to a report in the July Journal of Virology.

Virus-like particles are noninfectious proteins that closely mimic the properties of native virions, the authors explain, and HCV-LP have previously been shown to induce virus-specific immune responses in mice.

Dr. T. Jake Liang from National Institutes of Health, Bethesda, Maryland and colleagues evaluated the safety and immunogenicity of HCV-LP in a baboon model.

Immunized baboons showed a 100% seroconversion rate after the fourth immunization, the authors report, and the seroconversion rate after the third immunization increased from 0% to 100% with the use of adjuvants.

HCV-LP immunization also induced HCV-specific CD4+ and CD8+ T-cell responses, the report indicates. These responses were not significantly enhanced by the addition of adjuvants to the vaccine.

Boosting at 8 months markedly enhanced both humoral and cellular immune responses. "This suggests that boosting after an extended period of hiatus from the previous immunization is likely to be crucial in the activation and expansion of memory T- and B-cell responses to elicit a robust and long-lasting immune response in these animals," the investigators write.

HCV-LP immunization appeared to be superior to immunization with recombinant HCV vaccinia virus, the researchers note.

All baboons remained healthy without any signs of toxicity from the immunization or adjuvants.

"The scientific community is working very hard to advance our knowledge in the prevention and management of hepatitis C," Dr. Liang told Reuters Health. "Development of an HCV vaccine is possible."

Dr. Liang added, "We are testing this approach in chimpanzees now."

J Virol 2004;78:6995-7003.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.